Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L, Nguyen C, Everley RA, Trujillo JI, Johnson DS, Point GR, Thorarensen A, Kilty I, Telliez JB. Xu H, et al. Among authors: jesson mi. ACS Chem Biol. 2019 Jun 21;14(6):1235-1242. doi: 10.1021/acschembio.9b00188. Epub 2019 May 22. ACS Chem Biol. 2019. PMID: 31082193
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L, Stempora L, Hammond C, Wouters A, Mojcik CF, Cheng J, Collinge M, Jesson MI, Hazra A, Biswas P, Lan S, Clark JD, Hodge JA. Weinhold KJ, et al. Among authors: jesson mi. Clin Immunol. 2018 Jun;191:10-20. doi: 10.1016/j.clim.2018.03.002. Epub 2018 Mar 5. Clin Immunol. 2018. PMID: 29518577 Free PMC article. Clinical Trial.
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, Thompson JM, Happa FA, Stewart ZS, Zhan Y, Bollinger CS, Bansal PN, Wellen JW, Wilkie DP, Bailey SA, Symanowicz PT, Hegen M, Head RD, Kishore N, Mbalaviele G, Meyer DM. LaBranche TP, et al. Among authors: jesson mi. Arthritis Rheum. 2012 Nov;64(11):3531-42. doi: 10.1002/art.34649. Arthritis Rheum. 2012. PMID: 22899318 Free article.
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Ghoreschi K, et al. Among authors: jesson mi. J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7. J Immunol. 2011. PMID: 21383241 Free PMC article.
Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse.
LaBranche TP, Hickman-Brecks CL, Meyer DM, Storer CE, Jesson MI, Shevlin KM, Happa FA, Barve RA, Weiss DJ, Minnerly JC, Racz JL, Allen PM. LaBranche TP, et al. Among authors: jesson mi. Am J Pathol. 2010 Sep;177(3):1388-96. doi: 10.2353/ajpath.2010.100195. Epub 2010 Aug 9. Am J Pathol. 2010. PMID: 20696780 Free PMC article.
Mechanistic investigations of test article-induced pancreatic toxicity at the endocrine-exocrine interface in the rat.
Brenneman KA, Ramaiah SK, Rohde CM, Messing DM, O'Neil SP, Gauthier LM, Stewart ZS, Mantena SR, Shevlin KM, Leonard CG, Sokolowski SA, Lin H, Carraher DC, Jesson MI, Tomlinson L, Zhan Y, Bobrowski WF, Bailey SA, Vogel WM, Morris DL, Whiteley LO, Davis JW 2nd. Brenneman KA, et al. Among authors: jesson mi. Toxicol Pathol. 2014 Jan;42(1):229-42. doi: 10.1177/0192623313508851. Epub 2013 Nov 13. Toxicol Pathol. 2014. PMID: 24226507
21 results